| Detected | Trial | Change |
|---|---|---|
| 2026-07-07 | NCT06818643 A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced… |
Trial sites expanded: 45 -> 48 locations |
| 2026-07-07 | NCT07513376 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… |
Trial sites expanded: 10 -> 17 locations |
| 2026-07-07 | NCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated… |
Primary endpoint(s) modified |
| 2026-07-07 | NCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated… |
Trial arms changed: 1 -> 4 |
| 2026-07-07 | NCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-07-07 | NCT06780137 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab… |
Enrollment increased: 262 -> 327 participants |
| 2026-07-07 | NCT06780137 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab… |
date change Primary completion moved earlier: 2029-08-31 -> 2029-04-27 |
| 2026-07-07 | NCT06780137 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab… |
date change Completion moved earlier: 2030-01-17 -> 2029-04-27 |
| 2026-07-07 | NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer… |
date change Primary completion pushed: 2026-06-30 -> 2029-03-14 |
| 2026-07-07 | NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer… |
date change Completion pushed: 2028-07-31 -> 2029-03-14 |
| 2026-07-07 | NCT07190248 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With… |
Trial sites expanded: 181 -> 186 locations |
| 2026-07-07 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 41 -> 47 locations |
| 2026-07-07 | NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… |
Trial sites expanded: 115 -> 118 locations |
| 2026-07-03 | NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… |
Trial sites expanded: 307 -> 310 locations |
| 2026-07-03 | NCT07661108 A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) |
Recruitment opened |
| 2026-07-03 | NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… |
Trial sites expanded: 135 -> 138 locations |
| 2026-07-03 | NCT07519772 A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) |
Trial sites expanded: 8 -> 13 locations |
| 2026-07-03 | NCT07058077 A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and… |
Trial sites expanded: 30 -> 33 locations |
| 2026-07-03 | NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) |
Trial sites expanded: 5 -> 8 locations |
| 2026-07-02 | NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's… |
Trial terminated |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-30 | NCT07677163 A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) | Phase 1 | Not Yet Recruiting |
| 2026-06-22 | NCT07661108 A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) | Phase 1 | Recruiting |
| 2026-06-15 | NCT07646860 A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial… | Phase 2 | Not Yet Recruiting |
| 2026-06-08 | NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Phase 2/3 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07600723 | A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in… | Pulmonary Arterial Hypertension | Not Yet Recruiting |
| Phase 3 | |||
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Thrombocythemia, Essential | Recruiting |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Prostate Cancer Metastatic | Recruiting |
| NCT06655883 | A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants… | Insomnia | Recruiting |
| NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… | Leukemia, Lymphocytic, Chronic, B-Cell | Recruiting |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With… | Crohn Disease | Recruiting |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… | Endometrial Cancer | Recruiting |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting |
| NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS… | Non-small Cell Lung Cancer | Recruiting |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… | Colon Adenocarcinoma | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06456346 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | Essential Thrombocythemia | Recruiting |
| NCT07431827 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC… | Non-small Cell Lung Cancer | Recruiting |
| NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… | Non-small Cell Lung Cancer | Recruiting |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab… | Non Small Cell Lung Cancer | Recruiting |
| NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… | Breast Neoplasms | Recruiting |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… | Triple-Negative Breast Cancer | Recruiting |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in… | Non-small Cell Lung Cancer | Recruiting |
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants… | Crohn's Disease | Recruiting |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870)… | Ovarian Cancer | Recruiting |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… | Triple Negative Breast Neoplasms | Recruiting |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate… | Prostate Cancer | Recruiting |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Breast Neoplasms | Recruiting |
| NCT07071623 | A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | Human Immunodeficiency Virus (HIV) | Recruiting |